Compare COSM & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | IMNN |
|---|---|---|
| Founded | 2009 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 11.5M |
| IPO Year | 2009 | 2000 |
| Metric | COSM | IMNN |
|---|---|---|
| Price | $0.34 | $3.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 69.3K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,271,815.00 | N/A |
| Revenue This Year | $54.08 | N/A |
| Revenue Next Year | $32.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.93 | N/A |
| 52 Week Low | $0.28 | $0.37 |
| 52 Week High | $1.32 | $9.32 |
| Indicator | COSM | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 53.15 |
| Support Level | $0.29 | $3.00 |
| Resistance Level | $0.41 | $3.24 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 40.96 | 69.23 |
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.